Toxic epidermal necrolysis (TEN) is an uncommon and severe cutaneous adverse drug reaction that causes disseminated necrosis of epidermal cells and mucocutaneous detachment. Here, we report the case of a 32-year-old man with human immunodeficiency virus infection who presented with generalized violaceous macules and blister formation 4 days after the administration of mefenamic acid and amoxicillin for a dental procedure. Additional symptoms included oral ulcers and conjunctivitis. Results of skin biopsy were compatible with StevenseJohnson syndrome (SJS). SJS progressed to TEN within 2 days. Etanercept treatment showed a dramatic improvement in the symptoms of mucocutaneous lesions. To our knowledge, this is the first report on the treatment of TEN using etanercept in a human immunodeficiency virus-positive patient.
Introduction
StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions that cause disseminated epidermal necrosis. Both the conditions are associated with rapid generalized mucocutaneous detachment and can potentially result in death. 1 Individuals infected with human immunodeficiency virus (HIV) are particularly susceptible to the development of severe adverse cutaneous drug reactions such as TEN and SJS. 2, 3 Patients with SJS or TEN often receive systemic steroids for treating skin inflammation. However, complications because of steroid use such as infections and poor wound healing are a concern. Here, we report the case of an HIV-positive patient diagnosed with TEN based on the results of skin biopsy. When the patient was treated with etanercept, complete resolution of symptoms with no complications was seen.
Case report
A 32-year-old, HIV-seropositive but asymptomatic man presented to our emergency department with generalized skin eruptions and fever that had persisted for 1 day. He had been diagnosed with HIV infection in 2004 and had started receiving highly active antiretroviral medications in 2006. He had stopped taking his medication and missed his HIV follow-up appointment 7 months before he presented to our emergency department. He had no occurrence of opportunistic infections during the previous 7 months. The patient had undergone a dental procedure 4 days before presenting to our facility. Mefenamic acid and amoxicillin were prescribed for prophylactic use on the same day. He was not taking any Chinese herbs, health products, or other drugs. A high fever (>40 C) was noted 1 day before presentation. The sudden onset of generalized, painful, erythematous skin eruptions with blisters developed over the following 6 hours.
Physical examination revealed dissemination of generalized erythematous macules with a central purpuric hue (termed "atypical target lesions") on the patient's trunk, on all four limbs, and face ( Figure 1 ). Some macules were confluent, forming patches with bullae. Epidermal detachment involved 9% of the total body surface area (TBSA). There were multiple ulcers on the lips and oral mucosa. Bilateral conjunctivitis was also noted. Lymphadenopathy was not observed. Results of laboratory examinations showed a normal white blood cell count (7800 cells/mL; normal range, 3900e10,600 cells/mL), elevated serum creatinine level (1.36 mg/ dL; normal range, 0.64e1.27 mg/dL), elevated alanine transaminase level (42 U/L; normal range, 0e36 U/L), normal blood urine nitrogen (13.6 mg/dL; normal range, 6e21 mg/dL), elevated Creactive protein level (10.26 mg/L; normal range, <5 mg/L), normal fasting blood glucose level (90 mg/dL; normal range, 70e120 mg/ dL), decreased CD4 þ T cells (6.6%; normal range, 23e53%), and an elevated concentration of HIV RNA (20,789 copies/mL; normal range, negative). Results of arterial blood gas examination showed a normal bicarbonate level (25.9 mm/L; normal range, 22e26 mm/ L), while urine analysis revealed the presence of 1þ protein and trace glucose but not pyuria. A chest X-ray was normal, and the Tzanck smear test showed a negative morphological pattern for herpes virus. Results of skin biopsy showed a detached and totally necrotic epidermis and mild perivascular mononuclear cell infiltrates in the dermis ( Figure 2 ).
The pathological findings were compatible with SJS. Blood culture was negative for microbial growth. A diagnosis of SJS with a SCORTEN score of 1 was thus established. Results of lymphocyte transformation test were positive for amoxicillin and negative for mefenamic acid (Table 1 ). The patch test was also positive for amoxicillin and negative for mefenamic acid. Therefore, the probable causative agent was amoxicillin.
The patient received one dose of intravenous methylprednisolone (20 
Discussion
SJS and TEN constitute life-threatening, severe cutaneous adverse drug reactions and reflect a spectrum of the same condition. By definition, SJS causes epidermal detachment in <10% of the TBSA, whereas TEN involves >30% of the TBSA; overlapping SJS/TEN affects 10%e30% of the TBSA cases. 4 Clinically, SJS and TEN are characterized by the sudden onset of fever, followed by the development of generalized erythematous to violaceous maculopapules with blister formation. In addition, conjunctivitis and oral or genital ulcers may also develop. HIV-seropositive patients are more susceptible to cutaneous adverse drug reactions than the general population are. 3, 5 Furthermore, HIV-positive individuals have been shown to have a poorer prognosis 5 and longer hospitalization period than those who are HIV negative. 6, 7 The exact mechanisms underlying this augmented reaction in HIV-positive patients are still unclear, but The treatment strategy for SJS/TEN involves eliminating the causative agents and decreasing the inflammatory damage to the epidermis. Systemic steroid administration is frequently used for SJS/TEN. However, use of systemic steroid in HIV-positive individuals is still controversial.
12e14 Even a transient increase in HIV RNA levels was found after the administration of a systemic steroid.
14 Moreover, it has been reported that continued systemic steroid administration is not associated with improvements in mortality rates or wound healing in patients with SJS/TEN.
1,7
Infiltrates of cytotoxic T lymphocytes and increased amounts of TNF-a were observed in the epidermis of TEN lesions. 15 Paul et al 15 elucidated that TNF-a released by cytotoxic T lymphocytes could induce epidermal apoptosis by binding to TNF-a receptors on the cell surface of keratinocytes in TEN lesions. Then, extensive epidermal destruction began. Thus, TNF-a inhibitor may be an effective agent to decrease epidermal apoptosis among patients with TEN. Furthermore, higher serum levels of TNF-a are associated with HIV progression, including reduced immunocompetency and debilitating symptoms such as fever and cachexia. 16 Etanercept is a recombinant fusion protein that acts as a TNF-a inhibitor. The structure of etanercept includes a soluble TNF-a receptor linked to the F c subunit of human immunoglobulin G1. 17 Etanercept has been used for the treatment of TEN. 18, 19 Figure 4 Good progress in re-epithelialization was observed on the trunk. This photograph was taken on the 10 th day of hospitalization.
To the best of our knowledge, no previous reports describe the use of etanercept to treat STS/TEN in patients with HIV/AIDS. We show here that short-term etanercept treatment for SJS/TEN in patients with HIV/AIDS can be highly successful. Large randomized controlled studies should be performed to confirm the safety and efficacy of etanercept to treat SJS/TEN in patients with HIV/AIDS.
